BIOMAT Database Logo BIOMAT Database Logo

[Metastatic transitional cell carcinoma with high CA 19.9 serum levels]. 2007

Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Pôle des Maladies de l'Appareil Digestif, Hôpital Beaujon, Clichy.

We report the case of a 75-year-old woman with liver metastases of a urothelial carcinoma accompanied by a marked increased in CA 19-9 serum level. The mechanisms leading to this elevation, similar to that observed in biliary tract diseases, are discussed.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal
D018395 CA-19-9 Antigen Sialylated Lewis(a) blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors. 5-Acetylneuraminyl-2-3-Galactosyl-1-3-(Fucopyranosyl-1-4)-N-Acetylglucosamine,Antigen CA-19-9,Gastrointestinal Cancer Antigen,Sialyl Le(a),Sialyl Lewis A,Sialyl Lewis A Antigen,Sialyl Lewis(a) Tetrasaccharide,CA 19-9 Antigen,CA 19.9 Antigen,NAG-1,3-F-1,4-GN,Neu5Ac-2-3-Gal-1-3-(Fuc-1-4)-GlcNAc,alpha-Neu5Ac-(2-3)-beta-D-Gal-(1-3)-(alpha-L-Fuc-(1-4))-beta-D-GlcNAc,A, Sialyl Lewis,Antigen CA 19 9,Antigen, CA 19-9,Antigen, CA 19.9,Antigen, CA-19-9,CA 19 9 Antigen,CA-19-9, Antigen,Cancer Antigen, Gastrointestinal,Lewis A, Sialyl

Related Publications

Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Serum Ca 19.9 levels in thalassemia major.
May 1996, Pancreas,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Serum levels of CA 72.4, CEA and CA 19.9 in patients with colorectal carcinoma. Preliminary results.
January 1989, The International journal of biological markers,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
[Increased serum CA 19.9 in bronchiectasis].
January 2008, Revue des maladies respiratoires,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Serum levels of carbohydrate antigenic determinant (CA 19.9) in obstructive jaundice.
October 1989, Digestive diseases and sciences,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma.
January 1994, Anticancer research,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease.
January 2009, Medical principles and practice : international journal of the Kuwait University, Health Science Centre,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
[Presacral cyst and serum CA 19.9 raising].
January 2003, Gastroenterologia y hepatologia,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Small-cell lung cancer and elevated CA 19.9 tumor marker levels.
October 2012, Archivos de bronconeumologia,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern.
February 2019, Anticancer research,
Jean-Yves Camain, and Pascal Hammel, and Dominique Cazals-Hatem, and Philippe Levy, and Jacques Belghiti, and Philippe Ruszniewski
[Comparative analysis of serum levels of CA-50, CA-125, CA-19.9, enolase and CEA in bronchopulmonary cancer].
January 1987, Revue de pneumologie clinique,
Copied contents to your clipboard!